price target on Jefferies analyst Gena Wang maintained her Underperform rating and $7 PT on Sarepta Therapeutic (NASDAQ: SRPT), saying ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE